Clinical Trial Detail

NCT ID NCT02609503
Title Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

head and neck squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.